Genflow Biosciences plc
Genflow Biosciences plc (GENF.L) Company Profile & Overview
Explore Genflow Biosciences plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Genflow Biosciences plc (GENF.L) Company Profile & Overview
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.